Vertex Pharmaceuticals filings document the biotechnology company’s operating results, governance and product-development disclosures. Recent Form 8-K reports include quarterly and annual results releases, selected regulatory and pipeline events involving therapies such as povetacicept, and officer or director transition disclosures.
The company’s proxy materials cover board composition, director nominees, shareholder meeting matters, executive compensation and equity-award information. Vertex filings also provide formal records for disclosure topics tied to its approved medicines, clinical pipeline and governance structure as a Nasdaq-listed operating company.
Vertex Pharmaceuticals EVP and CMO Carmen Bozic reported an open-market sale of 6,988 shares of Common Stock at $450.00 per share. After this transaction, she directly holds 26,088 shares. The sale was carried out under a company-approved Rule 10b5-1 trading plan entered into on 11/20/2025.
Vertex Pharmaceuticals Inc. amendment to a Schedule 13G/A discloses that Capital World Investors beneficially owns 25,695,015 shares of Common Stock, equal to 10.1% of 254,034,190 shares outstanding as stated in the filing. The filing lists 25,556,582 shares as sole voting power and 25,695,015 as sole dispositive power. The amendment is signed May 13, 2026.
Vertex Pharmaceuticals Inc. ownership disclosure: Capital Research Global Investors reports beneficial ownership of 21,139,169 shares, representing 8.3% of the 254,034,190 shares believed outstanding as of the filing. The filer states sole voting power over 21,113,307 shares and sole dispositive power over 21,139,169 shares. The filing is signed by a Vice President and Senior Counsel of Capital Research and Management Company.
Vertex Pharmaceuticals held its annual shareholder meeting on May 13, 2026, where investors voted on board, compensation, auditor and governance matters. Shareholders elected ten directors, including Reshma Kewalramani and Jeffrey Leiden, each receiving over 209 million votes in favor.
Investors also approved the 2026 Stock and Option Plan, replacing the 2013 plan, with 216,097,268 votes for and 6,523,460 against. They ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, with 223,514,070 votes for. On an advisory basis, shareholders backed the 2025 executive compensation program, and they passed a shareholder proposal granting the right to act by written consent.
Vertex Pharmaceuticals reported Form 144 activity showing insider dispositions. The filing lists three open-market sales by Carmen Bozic of 2,329 shares each on 02/27/2026, 03/13/2026 and 03/27/2026, with gross proceeds of $1,118,641.99, $1,122,088.91 and $1,050,262.55 respectively. The excerpt also shows earlier restricted stock vesting entries from 02/10/2025 (3,102 shares), 02/17/2025 (2,040 shares) and 02/24/2025 (1,846 shares) recorded as compensation.
Vertex Pharmaceuticals filed a Form 144 notice reporting proposed sales of Common Stock by an affiliate and disclosed recent restricted stock vesting events. The filing lists vesting issuances to Fidelity Brokerage Services LLC on 02/13/2026, 02/17/2026, 02/24/2026, and 03/01/2026, and multiple proposed sales by Jonathan P. Biller on February 11–25, 2026.
Vertex Pharmaceuticals director Suketu Upadhyay reported routine equity compensation and a related share deferral. Upon vesting of previously granted restricted stock units, he exchanged 796 shares of common stock for 796 deferred stock units under the company’s deferred compensation plan, recording a disposition to the issuer and a matching derivative acquisition.
He also received a grant of 2,866 stock options exercisable at $424.45 per share, expiring on April 30, 2036. Following these transactions, he holds 1,558 shares of common stock, 3,595.156 deferred stock units, and 2,866 stock options, all reported as direct ownership.
Vertex Pharmaceuticals director Nancy Thornberry reported routine equity compensation changes. On May 1, 2026, she disposed of 398 shares of common stock back to the issuer in exchange for 398 deferred stock units under a deferred compensation plan, leaving 2,109 common shares at that step.
She then acquired 472 additional common shares as a grant, increasing her direct common stock holdings to 2,507 shares. Thornberry also received 398 deferred stock units, each linked to one share of common stock and payable upon specified future events, and a fully vested stock option for 1,433 shares with a $424.45 exercise price expiring on April 30, 2036.
Vertex Pharmaceuticals director Jennifer Schneider reported routine equity compensation changes. She disposed of 796 shares of common stock back to the company in exchange for 796 deferred stock units under a deferred compensation plan, so this was a non‑market, non‑cash swap rather than a sale.
Schneider also acquired 472 shares of common stock as a grant or award and received 796 deferred stock units, each representing one share of common stock payable upon certain future events. In addition, she was granted stock options for 1,433 shares at an exercise price of $424.45 per share, expiring in 2036, and now directly holds 2,190 shares of Vertex common stock.
Vertex Pharmaceuticals director Bruce I. Sachs reported an acquisition of stock options as compensation. He received a grant of 2,866 stock options for Vertex common stock at an exercise price of $424.45 per share. The options are fully vested and expire on April 30, 2036, and his direct derivative holdings after this grant total 2,866 options.